Hangzhou Diagens Biotechnology Co., Ltd. (Diagens-B) reported that its capital structure remained unchanged for the month ended 30 September 2026, according to the Monthly Return submitted to Hong Kong Exchanges and Clearing on 7 October 2026.

The company’s registered share capital stayed at 88.88 million ordinary H shares with a par value of RMB 1 each, matching the balance recorded at the end of August 2026. There were no new share issues, cancellations, repurchases, or treasury share movements during the period, leaving total issued shares at 88.88 million and zero treasury shares.

Diagens-B confirmed that its public float satisfies the Exchange’s minimum requirement set at 17.05 percent of issued H shares. All other potential equity-dilutive instruments—share options, warrants, convertibles and similar arrangements—remain “not applicable,” indicating no outstanding rights that could increase the share count.

Executive Director Song Ning affirmed that all statutory and regulatory obligations related to the company’s securities were met during the month, with no outstanding conditions pending regulatory compliance.